An Acorda Therapeutics drug, Ampyra (dalfampridine), which helps people with multiple sclerosis walk, also helps stroke patients who cannot walk, the company announced. In a proof-of- concept Phase II study, Ampyra (dalfampridine extended release 10mg tablets) significantly improved walking in patients with post-stroke deficits. Post-stroke deficits include impaired walking, motor and sensory function, as well as manual dexterity - collectively known as chronic neurological deficits. These deficits often persist in stroke victims. Ron Cohen, M.D...
More...
More...